Opthea (Australia) Today
| OPT Stock | 0.60 0.00 0.00% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Opthea is selling for under 0.6 as of the 27th of March 2025; that is No Change since the beginning of the trading day. The stock's last reported lowest price was 0.6. Opthea has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 27th of December 2024 and ending today, the 27th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | Category Healthcare | Classification Health Care |
Opthea is entity of Australia. It is traded as Stock on AU exchange. The company has 1.23 B outstanding shares. More on Opthea
Moving together with Opthea Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Opthea Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Opthea's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Opthea or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO MD | MAICD MAICD | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) | ||||
Opthea's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Opthea's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
| Debt LevelsOpthea can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Opthea's financial leverage. It provides some insight into what part of Opthea's total assets is financed by creditors.
LiquidityOpthea cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. Opthea has accumulated 141.65 M in total debt. Debt can assist Opthea until it has trouble settling it off, either with new capital or with free cash flow. So, Opthea's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Opthea sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Opthea to invest in growth at high rates of return. When we think about Opthea's use of debt, we should always consider it together with cash and equity.
| |||||
Opthea (OPT) is traded on Australian Securities Exchange in Australia and employs 33 people. Opthea is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 738.75 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Opthea's market, we take the total number of its shares issued and multiply it by Opthea's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Opthea operates under Biotechnology sector and is part of Health Care industry. The entity has 1.23 B outstanding shares.
Opthea has accumulated about 77.12 M in cash with (161.02 M) of positive cash flow from operations.
Check Opthea Probability Of Bankruptcy
Ownership AllocationOpthea owns a total of 1.23 Billion outstanding shares. 30% of Opthea outstanding shares are owned by third-party entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Opthea Ownership Details
Opthea Risk Profiles
Although Opthea's alpha and beta are two of the key measurements used to evaluate Opthea's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 3.2 | |||
| Standard Deviation | 4.26 | |||
| Variance | 18.11 | |||
| Risk Adjusted Performance | 0.0019 |
Opthea Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Opthea without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Global Correlations Now
Global CorrelationsFind global opportunities by holding instruments from different markets |
| All Next | Launch Module |
Opthea Corporate Management
Elected by the shareholders, the Opthea's board of directors comprises two types of representatives: Opthea inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opthea. The board's role is to monitor Opthea's management team and ensure that shareholders' interests are well served. Opthea's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opthea's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jen Watts | VP Operations | Profile | |
| Karen CPA | VP Secretary | Profile | |
| CPA CPA | Chief Officer | Profile | |
| Sarika Gulhar | Executive Resources | Profile | |
| MD MA | Chief Board | Profile | |
| Michael Gerometta | Manufacturing Chemistry | Profile | |
| Peter MBA | Chief Officer | Profile |
Additional Tools for Opthea Stock Analysis
When running Opthea's price analysis, check to measure Opthea's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opthea is operating at the current time. Most of Opthea's value examination focuses on studying past and present price action to predict the probability of Opthea's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opthea's price. Additionally, you may evaluate how the addition of Opthea to your portfolios can decrease your overall portfolio volatility.